Biohaven

Overview

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is an American pharmaceutical company headquartered in New Haven, Connecticut, focused on developing novel therapies for neurological and immunological diseases. The company has built a significant pipeline targeting neurodegenerative disorders, particularly Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)[@biohaven].

Overview

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is an American pharmaceutical company headquartered in New Haven, Connecticut, focused on developing novel therapies for neurological and immunological diseases. The company has built a significant pipeline targeting neurodegenerative disorders, particularly Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)[@biohaven].

Funding

• IPO: 2017 (NYSE: BHVN)
• Acquired: 2023 by Pfizer ($43B)
• Prior Funding: Series A-C, IPO

Company Information

| Attribute | Value |
|-----------|-------|
| Founded | 2013 |
| Headquarters | New Haven, Connecticut, USA |
| Ticker | NYSE: BHVN |
| CEO | Matthew Buten |
| Market Cap | ~$1.5B (2025) |
| Employees | ~300 |
| R&D Budget | ~$200M/year (2024) |

History

Biohaven was founded in 2013 as a spin-off company focused on developing novel CNS therapeutics. The company went public in 2017 on NASDAQ and transferred to NYSE in 2022[@biohaven].

Key milestones:

• 2017: Initial public offering (NASDAQ: BHVN)
• 2018: Acquired Kv7 potassium channel modulators from Bristol-Myers Squibb
• 2020: Troriluzole entered Phase 3 trials for ALS
• 2022: Multiple pipeline expansions in neurodegeneration

Technology Platform

Kv7 Potassium Channel Modulators

Biohaven's core technology platform focuses on Kv7.2/7.3 (KCNQ2/3) potassium channel activators[@milligan2020]:

• Mechanism: Kv7 channels regulate neuronal hyperexcitability by stabilizing the resting membrane potential
• Therapeutic Rationale: Neuronal hyperexcitability is implicated in multiple neurodegenerative disorders
• Advantages: Oral bioavailability, established safety profile, [blood-brain barrier](/entities/blood-brain-barrier) penetration

TDP-43 Targeting

Biohaven is developing therapeutics targeting TDP-43 protein pathology:

• TDP-43 aggregates are found in 95% of ALS cases and 50% of Alzheimer's disease
• BHVN-3744 aims to reduce TDP-43 pathology through novel mechanisms[@rohn2023]

Neurodegeneration Pipeline

Alzheimer's Disease (AD)

| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| BHVN-4151 (Troriluzole) | Kv7.2/7.3 activator | Phase 2 | Active |
| BHVN-7010 | Next-gen Kv7 activator | Phase 1 | Active |
| BHVN-3744 | TDP-43 modulator | Preclinical | Research |

Troriluzole in AD: Originally developed for epilepsy, troriluzole is being repurposed for AD based on preclinical data showing:

• Reduction in [amyloid-beta](/proteins/amyloid-beta) toxicity
• Neuroprotective effects in cellular models
• Potential to improve synaptic function[@milligan2020]

Parkinson's Disease (PD)

| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| BHVN-4151 | Kv7 activator | Phase 2 | Active |
| BHVN-3744 | TDP-43 | Preclinical | Research |

Rationale: Kv7 modulators may protect dopaminergic [neurons](/entities/neurons) from:

• Oxidative stress
• [Mitochondrial](/mechanisms/mitochondrial-dysfunction) dysfunction
• [Neuroinflammation](/mechanisms/neuroinflammation)

Amyotrophic Lateral S sclerosis (ALS)

| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| Troriluzole (BHVN-4157) | Kv7.2/7.3 activator | Phase 3 | Completed enrollment |
| BHVN-3744 | TDP-43 | Preclinical | Research |

Phase 3 Trial (NCT04948645): Troriluzole was evaluated in patients with definite or probable ALS. Primary endpoint was survival or respiratory decline. Results expected 2025-2026[@biohavena].

Other Neurological Programs

• BHVN-5000: NMDA antagonist for Rett syndrome (Phase 2)
• BHVN-3000: novel mechanism for treatment-resistant depression

Clinical Development Strategy

Biohaven's approach to neurodegeneration:

Key Partnerships

• Bristol-Myers Squibb: Kv7 technology acquisition and ongoing collaboration
• University of Pennsylvania: TDP-43 research collaboration
• ALS Association: Clinical trial partnerships
• Various Academic Centers: Clinical trial sites worldwide

Financial Highlights

| Year | Revenue | R&D Expenses | Cash Position |
|------|---------|--------------|----------------|
| 2022 | $42M | $185M | $280M |
| 2023 | $58M | $210M | $265M |
| 2024 | ~$70M | ~$200M | ~$250M |

Competitive Landscape

Biohaven competes with other pharmaceutical companies in the neurodegeneration space:

| Company | Key Programs | Mechanism |
|---------|--------------|-----------|
| Amylyx | AMX0035 | [UPR](/entities/unfolded-protein-response)/PR activation |
| Cytokinetics | Reldesparlate | SOD1 aggregation |
| Biogen | [Lecanemab](/entities/lecanemab), Aduhelm | Amyloid clearance |
| AbbVie | ABBV-951 | Gene therapy |
| Biohaven | Troriluzole, Kv7 | Ion channel modulation |

See Also

• [Alzheimer's Disease - Therapeutic Approaches](/diseases/alzheimers-disease)
• [Parkinson's Disease - Drug Development](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis - Clinical Trials](/diseases/amyotrophic-lateral-sclerosis)
• [Kv7 Potassium Channels](/proteins/kcnq2-protein)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)

External Links

• [Biohaven Corporate Website](https://www.biohaven.com)
• [ClinicalTrials.gov - Biohaven](https://clinicaltrials.gov/search?spons=Biohaven)
• [PubMed - Biohaven](https://pubmed.ncbi.nlm.nih.gov/?term=Biohaven+neurodegeneration)

References